Myriad Genetics
MYGN
239 hedge funds and large institutions have $2.12B invested in Myriad Genetics in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 74 increasing their positions, 88 reducing their positions, and 30 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
33% more call options, than puts
Call options by funds: $18.8M | Put options by funds: $14.1M
32% more capital invested
Capital invested by funds: $1.61B → $2.12B (+$516M)
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
3% more funds holding
Funds holding: 233 → 239 (+6)
2.31% less ownership
Funds ownership: 123.04% → 120.73% (-2.3%)
16% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$57.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$16.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$12.4M |
| 4 |
PP
PDT Partners
New York
|
+$6.97M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$6.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28.1M |
| 2 |
BTS
BB&T Securities
Richmond,
Virginia
|
-$15M |
| 3 |
Millennium Management
New York
|
-$12.9M |
| 4 |
Renaissance Technologies
New York
|
-$10.3M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$9.96M |
MYGN Hedge Fund Activity: Q2 2017 in Review
239 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2017, worth a combined $2.12B — up 32% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MYGN positions and 30 closed out — a net gain of 6 holders — while 74 added to existing stakes and 88 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $57.4M. The largest seller was Camber Capital Management, cutting an estimated $28.1M.
- 239 institutional investors held Myriad Genetics (MYGN) as of Q2 2017, up from 233 in Q1 2017.
- Funds reported $2.12B of Myriad Genetics stock for Q2 2017, up 32% quarter-over-quarter.
- 36 funds opened new Myriad Genetics positions in Q2 2017 and 30 closed out, a net change of +6 holders.
- The largest Myriad Genetics buyer in Q2 2017 was Thrivent Financial for Lutherans, an estimated $57.4M added.
- The largest Myriad Genetics seller in Q2 2017 was Camber Capital Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q2 2017.